Overview of the immune monitoring results
| Peptide-specific immune respones | September 13, 2018 (V9) | March 14, 2019 (V17) | July 08, 2019 (post V18) | |||||||
| No. | Peptide sequence | Gene and somatic variant | HLA | VAF (%) | CD4 | CD8 | CD4 | CD8 | CD4 | CD8 |
| 1 | HSYRGTGGIFK | TBL1XR1 NM_024665 c.G1462A:p.E488K | HLA-A*03:01 | 36 | – | – | ++ SI: 4.3 (1.7%) | + SI: 2.1 (0.6%) | Pool peptide 1+5 +++ SI: 7.3 (0.4%) | Pool peptide 1+5 ++++ SI: 15.9 (6.5 %) |
| 2 | MMFRNYQRK | CHD4 NM_001273 c.G1705A:p.V569M | HLA-A*03:01 | 38 | – | – | – | ++ SI: 3.8 (1,8%) | – | + SI: 3.2 (0.6 %) |
| 3 | EVSAAHRAHYF | DNMT3A NM_022552.4 c.G2375A:p.R792H | HLA-A*26:01 | 36 | +++ SI: 7.7 (1.1%) | (+) positive tendency | + SI: 2.2 (0.6%) | – | Pool peptide 3+7 ++++ SI: 21.6 (1.8%) | Pool peptide 3+7 – |
| 4 | DPTASVPSM | KIAA1549 NM_001164665 c.G4753A:p.V1585M | HLA-B*35:01 | 33 | +++ SI: 5.6 (4.3%) | – | ++ SI: 3.7 (1.6%) | – | Pool peptide 4+6 ++++ SI: 11.6 (0.5%) | Pool peptide 4+6 – |
| 5 | HIPIIWATSY | PIK3C2B NM_002646 c.G1919A:p.R640H | HLA-A*26:01 | 45 | – | – |
++++
SI: 13.1 (6,6%) | +++ SI: 6.2 (2.9%) | Pool peptide 1+5 +++ SI: 7.3 (0.4%) | Pool peptide 1+5 ++++ SI: 15.9 (6.5 %) |
| 6 | VQRRAQGKLF | KEL NM_000420 c.A869T:p.E290V | HLA-B*15:01 | 37 | – | – | – | + SI: 2.1 (1.0%) | Pool peptide 4+6 ++++ SI: 11.6 (0.5) | Pool peptide 4+6 – |
| 7 | AFDDKTRLV | WWC3 NM_015691 c.T662C:p.V221A | HLA-C*04:01 | 33 | – | – | – | – | Pool peptide 3+7 ++++ SI: 21.6 (1.8%) | Pool peptide 3+7 – |
| 8 | TGVPQSRPHIPRTQPQP | RNF43 NM_017763.4 c.C1742A:p.P581H | Class II | 36 | ++++ SI: 39.3 (1.7%) | – | + SI: 2.5 (0.7%) | – | ++ SI: 4.1 (0.3 %) | – |
| 9 | MFKGVASSQFLPKGTKT | SETD2 NM_014159.6 c.G158A:p.R53Q | Class II | 38 | ++++ SI: 37.5 (0.9%) | – | +++ SI: 9.5 (2.0%) | – |
++++
SI: 35.9 (2.4%) | – |
| 10 | DWNPHQDLHAQDRAHRI | SMARCA4 NM_001128844.1 c.A3555T:p.Q1185H | Class II | 33 | – | – | – | – | – | – |
HLA: human leukocyte antigen type, for which binding was predicted. VAF: variant allele frequency, detection frequency of the mutated allele. The observed frequencies could be influenced by tumor content and copy number variations and do not directly equal the proportion of the mutation in the tumor. SI: Stimulation Index, x-fold increase of polyfunctional reactive T cells (at least two of the markers CD154, IFN-γ, TNF and/or IL-2 positive) in the stimulated specimen compared to the according negative control specimen. Additional information: proportion (%) of reactive T cells (IFN-γ, TNF, IL-2 and/or CD154 positive) of the CD4+ or CD8+ T cell population after in vitro amplification. Does not directly equal the frequency of specific cells in vivo. +, lightly positive; ++, positive; +++, strongly positive; ++++, very strongly positive; IFN, interferon; TNF, tumor necrosis factor; IL, interleukin.